Bionomics Debt to Equity Ratio 2022-2024 | NEUP
Current and historical debt to equity ratio values for Bionomics (NEUP) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Bionomics debt/equity for the three months ending September 30, 2024 was 0.00.
| Bionomics Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-09-30 |
$0.01B |
$0.02B |
0.34 |
| 2024-06-30 |
$0.01B |
$0.02B |
0.58 |
| 2023-12-31 |
$0.01B |
$0.02B |
0.34 |
| 2023-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2023-06-30 |
$0.01B |
$0.02B |
0.30 |
| 2022-12-31 |
$0.01B |
$0.03B |
0.18 |
| 2022-06-30 |
$0.01B |
$0.04B |
0.15 |
| 2021-06-30 |
$0.01B |
$0.04B |
0.14 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.010B |
$0.000B |
|
Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.
|
